Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.7%

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) were up 3.7% during trading on Monday . The stock traded as high as $24.99 and last traded at $24.91. 86,715 shares were traded during trading, a decline of 91% from the average session volume of 934,340 shares. The stock had previously closed at $24.02.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays upped their price objective on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. increased their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Oppenheimer boosted their target price on Nurix Therapeutics from $25.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th. Truist Financial started coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target for the company. Finally, Needham & Company LLC lowered their price target on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, July 12th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $26.69.

Check Out Our Latest Research Report on Nurix Therapeutics

Nurix Therapeutics Price Performance

The company has a market cap of $1.26 billion, a price-to-earnings ratio of -8.76 and a beta of 2.22. The firm has a fifty day simple moving average of $21.17 and a 200 day simple moving average of $16.40.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last posted its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). The firm had revenue of $12.09 million during the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. Analysts expect that Nurix Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 1,900 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $17.01, for a total transaction of $32,319.00. Following the completion of the sale, the insider now owns 19,838 shares in the company, valued at approximately $337,444.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Houte Hans Van sold 3,477 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $21.45, for a total value of $74,581.65. Following the completion of the sale, the chief financial officer now owns 51,002 shares in the company, valued at $1,093,992.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christine Ring sold 1,900 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $17.01, for a total value of $32,319.00. Following the transaction, the insider now owns 19,838 shares in the company, valued at $337,444.38. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,791 shares of company stock worth $506,063. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NRIX. Teachers Retirement System of The State of Kentucky bought a new position in shares of Nurix Therapeutics during the 2nd quarter worth about $578,000. Driehaus Capital Management LLC bought a new position in Nurix Therapeutics during the second quarter worth about $26,778,000. The Manufacturers Life Insurance Company lifted its stake in Nurix Therapeutics by 25.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock worth $479,000 after purchasing an additional 4,583 shares during the period. Millennium Management LLC boosted its holdings in Nurix Therapeutics by 60.2% during the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after purchasing an additional 225,374 shares in the last quarter. Finally, Dark Forest Capital Management LP bought a new stake in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $201,000.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Further Reading

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.